- Home
- ALLR vs LPCN Comparison
ALLR vs LPCN Comparison
Compare ALLR & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLR
- LPCN
- Stock Information
- Founded
- ALLR 2004
- LPCN 1997
- Country
- ALLR United States
- LPCN United States
- Employees
- ALLR N/A
- LPCN N/A
- Industry
- ALLR Biotechnology: Pharmaceutical Preparations
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- ALLR Health Care
- LPCN Health Care
- Exchange
- ALLR Nasdaq
- LPCN Nasdaq
- Market Cap
- ALLR 15.8M
- LPCN 16.1M
- IPO Year
- ALLR N/A
- LPCN N/A
- Fundamental
- Price
- ALLR $1.01
- LPCN $3.15
- Analyst Decision
- ALLR Strong Buy
- LPCN Strong Buy
- Analyst Count
- ALLR 1
- LPCN 2
- Target Price
- ALLR $9.00
- LPCN $9.00
- AVG Volume (30 Days)
- ALLR 536.3K
- LPCN 37.3K
- Earning Date
- ALLR 08-08-2025
- LPCN 08-11-2025
- Dividend Yield
- ALLR N/A
- LPCN N/A
- EPS Growth
- ALLR N/A
- LPCN N/A
- EPS
- ALLR N/A
- LPCN N/A
- Revenue
- ALLR N/A
- LPCN $3,674,834.00
- Revenue This Year
- ALLR N/A
- LPCN N/A
- Revenue Next Year
- ALLR N/A
- LPCN N/A
- P/E Ratio
- ALLR N/A
- LPCN N/A
- Revenue Growth
- ALLR N/A
- LPCN N/A
- 52 Week Low
- ALLR $0.61
- LPCN $2.68
- 52 Week High
- ALLR $6.00
- LPCN $6.17
- Technical
- Relative Strength Index (RSI)
- ALLR 49.17
- LPCN 45.50
- Support Level
- ALLR $1.03
- LPCN $3.24
- Resistance Level
- ALLR $1.17
- LPCN $3.45
- Average True Range (ATR)
- ALLR 0.08
- LPCN 0.20
- MACD
- ALLR -0.00
- LPCN 0.00
- Stochastic Oscillator
- ALLR 28.89
- LPCN 25.00
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.